BioSpace News Archive

Zynex, Inc. announced today that it will host the Company’s 2021 second quarter earnings investor webcast on Thursday, July 29,2021 at 2:15 p.m. Mountain Time.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today new data for valoctocogene roxaparvovec, an investigational gene therapy treatment for adults with severe hemophilia A, from its open-label Phase 1/2 study during an oral presentation at the International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress.

Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced updated data from the ongoing Phase 1/2 clinical trial of investigational SPK-8011 in hemophilia A during the International Society of Thrombosis and Hemostasis (ISTH) 2021 Virtual Congress (July 17-21).

Prior to this appointment, Benjamin Krantz MD, MBA was the Chief Fellow in hematology/oncology at New York University Langone Medical Center and served on the Board of Directors of APTI.

The magnetic resonance imaging market is expected to reach US$ 7,955.1 Mn in 2025 from US$ 5,913.6 in 2017

The oral care market was valued at US$ 36,273.14 million in 2020 and is projected to reach US$ 47,380.58 million by 2028; it is expected to grow at a CAGR of 3.4% from 2021 to 2028.

Onco360®, the nation’s largest independent Oncology Pharmacy, has been selected by Kadmon Pharmaceuticals, LLC to be a specialty pharmacy partner for REZUROCK (belumosudil), a new oral treatment for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.

X-Vax Technology, Inc., a biotechnology company developing vaccines based on a new approach that mediates the killing of infected cells, announced the appointment of Varsha K. Jain, MD as Chief Clinical Development Officer.

Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, announced that its product FINTEPLA® (fenfluramine) oral solution has been recognized by two distinguished clinicians in an Epilepsy & Behavior editorial titled “Raising the Bar: Fenfluramine Sets New Treatment Standards for Dravet Syndrome.”

Viracta Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared Viracta’s Investigational New Drug (IND) application to proceed into a Phase 1b/2 trial in patients with EBV+ recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) and other EBV+ solid tumors.